Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG002 in HER2-positive/HER2-low Advanced Gastric/GEJ Cancer
NCT05141747Phase 2Unknown
- Sponsor
- Hangzhou Miracogen
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MRG002 in gastric cancer (GC) and gastroesophageal junction cancer, sponsored by Hangzhou Miracogen. Primary endpoints: Objective Response Rate up to 24 months and Adverse Events. Status: unknown.
02
Drugs
MRG002
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05141747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05141747.